BRPI0416141B8 - anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina - Google Patents

anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina

Info

Publication number
BRPI0416141B8
BRPI0416141B8 BRPI0416141A BRPI0416141A BRPI0416141B8 BR PI0416141 B8 BRPI0416141 B8 BR PI0416141B8 BR PI0416141 A BRPI0416141 A BR PI0416141A BR PI0416141 A BRPI0416141 A BR PI0416141A BR PI0416141 B8 BRPI0416141 B8 BR PI0416141B8
Authority
BR
Brazil
Prior art keywords
immunoglobulin
antibody
preparing
pharmaceutical composition
expression vectors
Prior art date
Application number
BRPI0416141A
Other languages
English (en)
Inventor
A Hamilton Anita
J Carr Francis
Original Assignee
Biovation Ltd
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovation Ltd, Merck Patent Gmbh filed Critical Biovation Ltd
Publication of BRPI0416141A publication Critical patent/BRPI0416141A/pt
Publication of BRPI0416141B1 publication Critical patent/BRPI0416141B1/pt
Publication of BRPI0416141B8 publication Critical patent/BRPI0416141B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpo anti-cd52 modificado. a presente invenção fornece formas modificadas de anticorpos anti-cd52 com números reduzidos de epítopos de células t potenciais que se espera apresentarem imunogenicidade reduzida.
BRPI0416141A 2003-11-01 2004-10-29 anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina BRPI0416141B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51621003P 2003-11-01 2003-11-01
US60/516,210 2003-11-01
PCT/IB2004/003879 WO2005042581A2 (en) 2003-11-01 2004-10-29 Modified anti-cd52 antibody

Publications (3)

Publication Number Publication Date
BRPI0416141A BRPI0416141A (pt) 2007-01-02
BRPI0416141B1 BRPI0416141B1 (pt) 2019-01-15
BRPI0416141B8 true BRPI0416141B8 (pt) 2021-05-25

Family

ID=34549504

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416141A BRPI0416141B8 (pt) 2003-11-01 2004-10-29 anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina

Country Status (11)

Country Link
US (3) US7264806B2 (pt)
EP (1) EP1694706B1 (pt)
JP (1) JP4804357B2 (pt)
CN (1) CN1898267B (pt)
AT (1) ATE552276T1 (pt)
BR (1) BRPI0416141B8 (pt)
CA (1) CA2544365A1 (pt)
DK (1) DK1694706T3 (pt)
ES (1) ES2384105T3 (pt)
PT (1) PT1694706E (pt)
WO (1) WO2005042581A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
AU2011202920C1 (en) * 2006-05-30 2012-11-15 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
WO2009014835A2 (en) * 2007-06-21 2009-01-29 Angelica Therapeutics, Inc. Modified toxins
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
US8569460B2 (en) * 2009-03-25 2013-10-29 Vet Therapeutics, Inc. Antibody constant domain regions and uses thereof
WO2010132683A1 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treating lupus
EP3683317A3 (en) 2009-05-13 2020-09-30 Genzyme Corporation Anti-human cd52 immunoglobulins
GB0914691D0 (en) * 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
EP2542258A4 (en) * 2010-03-04 2013-08-21 Vet Therapeutics Inc ON CD52 MONOCLONAL ANTIBODIES
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
AR084141A1 (es) 2010-11-19 2013-04-24 Imai Toshio Anticuerpos neutralizadores anti-ccl20
EP2670422B1 (en) 2011-02-02 2018-10-17 Emory University Antagonism of the vip signaling pathway
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
EP2952210A3 (en) 2011-04-07 2016-03-16 Emory University Compositions comprising saccharide binding moieties and methods for targeted therapy
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
HK1220376A1 (zh) 2013-03-15 2017-05-05 Angelica Therapeutics, Inc. 修饰的毒素
CA2907397C (en) * 2013-03-15 2022-11-22 Anthrogenesis Corporation Modified t lymphocytes
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
WO2016059377A1 (en) 2014-10-14 2016-04-21 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
WO2016196935A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
JP2020517256A (ja) 2017-04-19 2020-06-18 エルスター セラピューティクス， インコーポレイテッド 多重特異性分子およびその使用
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
EP3720881A1 (en) 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2019209952A2 (en) 2018-04-23 2019-10-31 Emory University Vip antagonists and uses in treating cancer
CN113164777B (zh) 2018-09-27 2024-12-13 马伦戈治疗公司 Csf1r/ccr2多特异性抗体
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
JP2024543822A (ja) 2021-11-03 2024-11-26 アフィメド ゲーエムベーハー 二重特異性ｃｄ１６ａバインダー

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ATE174058T1 (de) 1989-11-06 1998-12-15 Cell Genesys Inc Herstellung von proteinen mittels homologer rekombination
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US5846543A (en) 1995-10-24 1998-12-08 Hassler; Mark A. Bovine mastitis treatment
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
EP1051432B1 (en) * 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
JP4334866B2 (ja) 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
AU2002256624B2 (en) * 2001-02-19 2007-12-06 Merck Patent Gmbh Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
US7524502B2 (en) * 2001-11-12 2009-04-28 Merck Patent Gmbh Modified anti-TNF alpha antibody
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies

Also Published As

Publication number Publication date
US20080075715A1 (en) 2008-03-27
US20080248529A1 (en) 2008-10-09
BRPI0416141B1 (pt) 2019-01-15
DK1694706T3 (da) 2012-07-16
ATE552276T1 (de) 2012-04-15
CA2544365A1 (en) 2005-05-12
JP4804357B2 (ja) 2011-11-02
US7910104B2 (en) 2011-03-22
WO2005042581A8 (en) 2006-06-29
BRPI0416141A (pt) 2007-01-02
US7264806B2 (en) 2007-09-04
JP2007534304A (ja) 2007-11-29
PT1694706E (pt) 2012-06-19
ES2384105T3 (es) 2012-06-29
CN1898267B (zh) 2012-05-23
WO2005042581A2 (en) 2005-05-12
WO2005042581A3 (en) 2005-07-28
CN1898267A (zh) 2007-01-17
EP1694706A2 (en) 2006-08-30
US20050152898A1 (en) 2005-07-14
EP1694706B1 (en) 2012-04-04

Similar Documents

Publication Publication Date Title
ATE552276T1 (de) Modifizierter anti-cd52-antikörper
MX2024004322A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
MX386942B (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
MX2024001190A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
CY1113089T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma)
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
UA92505C2 (ru) Композиции на основе антитела против cd3
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
DK2142570T3 (da) Anti-EpCam-antistof og anvendelser deraf
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
TW200745161A (en) Stable antibody formulation
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
WO2018119351A8 (en) Anti-sez6l2 antibodies and antibody drug conjugates
ATE395082T1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
BR112013002831A2 (pt) anticorpos direcionados contra a il-17
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERCK PATENT GMBH (DE)

Free format text: TRANSFERIDO DE: BIOVATION LIMITED

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/10/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2853 DE 09-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.